<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00875277</url>
  </required_header>
  <id_info>
    <org_study_id>PLQ-003</org_study_id>
    <nct_id>NCT00875277</nct_id>
  </id_info>
  <brief_title>A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products</brief_title>
  <official_title>A Psoriasis Plaque Test Comparing LEO 29102 Cream and Its Different Combinations to DaivobetÂ® Ointment and a Vehicle Control for the Treatment of Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the anti-psoriatic effect of LEO 29102 cream and its
      combination with calcipotriol and betamethasone using a psoriasis plaque test method.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Clinical Score of the clinical symptoms</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical scores, lesions thickness, histology and immunohistochemistry measurements</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>LEO 29102 cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 29102 cream and combination products</intervention_name>
    <description>Once daily application 6 days a week for 4 weeks</description>
    <arm_group_label>LEO 29102 cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: (in summary)

          -  Subjects having understood and signed an informed consent form

          -  All skin types

          -  Subjects with a diagnosis of psoriasis vulgaris with lesions located on arms, legs or
             trunk. The lesions must have a total size suitable for application. The subjects
             should be asked if their lesions have been stable

          -  Subjects willing and able to follow all the study procedures and complete the whole
             study

          -  Subjects affiliated to social security system

        Exclusion Criteria: (in summary)

          -  Females who are pregnant, of child-bearing potential and who wish to become pregnant
             during the study, or who are breast feeding

          -  Subjects using biological therapies (marketed or not marketed) with a possible effect
             on psoriasis (e.g. alefacept, efalizumab, etanercept, infliximab, adalimumab) within
             12 weeks prior to study drug administration

          -  Systemic treatments with all other therapies than biologicals, with a potential effect
             on psoriasis vulgaris (e.g., corticosteroids, vitamin D-analogues, retinoids,
             immunosuppressants) within the 4-week period prior to randomisation

          -  Subjects using one of the following topical drugs for the treatment of psoriasis
             within four (4) weeks prior to study drug administration: - Potent or very potent (WHO
             group III-IV) corticosteroids - PUVA or Grenz ray therapy

          -  Subjects using one of the following topical drugs for the treatment of psoriasis
             within two (2) weeks prior to study drug administration: - WHO group I-II
             corticosteroids - Topical retinoids - Vitamin D-analogues - Topical immunomodulators
             (e.g. macrolides) - Anthracen derivatives - Tar - Salicylic acid - UVB therapy

          -  Subjects with skin manifestations in relation to syphilis or tuberculosis, rosacea,
             perioral dermatitis, acne vulgaris, atrophic skin, striae atrophicae, fragility of
             skin veins, ichthyosis, acne rosacea, ulcers and wounds within the plaque test areas
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Director, International Clinical Development, MD</last_name>
    <role>Study Director</role>
    <affiliation>LEO Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LEO Pharma site</name>
      <address>
        <city>St Quentin Yvelines Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2009</study_first_submitted>
  <study_first_submitted_qc>April 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2009</study_first_posted>
  <last_update_submitted>October 24, 2013</last_update_submitted>
  <last_update_submitted_qc>October 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

